Addus HomeCare (ADUS) Projected to Post Quarterly Earnings on Monday

Key Points

• Addus HomeCare is projected to report Q1 2026 results after market close on Monday, May 4, with analysts expecting $1.55 EPS and $366.36 million in revenue, and will host a call on May 5 at 9:00 AM ET.
• The stock trades near $95.71 with a market capitalization of about $1.79 billion and a PE of 18.37, and carries an average analyst rating of "Moderate Buy" with an average target price of $133.22.
• Insiders sold roughly 16,788 shares (about $1.79 million) over the last quarter, while institutional investors hold approximately 95.35% of the company’s stock.

Addus HomeCare (NASDAQ:ADUS - Get Free Report) is projected to issue its Q1 2026 results after the market closes on Monday, May 4th. Analysts expect the company to announce earnings of $1.55 per share and revenue of $366.36 million for the quarter. Parties are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 9:00 AM ET.

Addus HomeCare Price Performance

Shares of ADUS opened at $95.71 on Monday. The business's 50 day moving average is $100.06 and its 200 day moving average is $108.26. The company has a market capitalization of $1.79 billion, a PE ratio of 18.37, a price-to-earnings-growth ratio of 1.32 and a beta of 0.96. Addus HomeCare has a 12-month low of $90.89 and a 12-month high of $124.43. The company has a current ratio of 1.80, a quick ratio of 1.80 and a debt-to-equity ratio of 0.11.

Wall Street Analyst Weigh In

Several analysts recently issued reports on ADUS shares. Barclays decreased their target price on Addus HomeCare from $112.00 to $102.00 and set an "underweight" rating on the stock in a research note on Wednesday, March 25th. Wall Street Zen downgraded Addus HomeCare from a "strong-buy" rating to a "buy" rating in a research note on Saturday, March 21st. Royal Bank Of Canada reissued an "outperform" rating and set a $139.00 target price on shares of Addus HomeCare in a research note on Wednesday, February 25th. Weiss Ratings reissued a "hold (c+)" rating on shares of Addus HomeCare in a research note on Wednesday, January 21st. Finally, Stephens decreased their target price on Addus HomeCare from $140.00 to $135.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $133.22.

Insiders Place Their Bets

In other Addus HomeCare news, EVP Roberton James Stevenson sold 284 shares of Addus HomeCare stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $105.36, for a total value of $29,922.24. Following the sale, the executive vice president owned 14,030 shares of the company's stock, valued at $1,478,200.80. The trade was a 1.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Michael D. Wattenbarger sold 300 shares of Addus HomeCare stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $105.36, for a total value of $31,608.00. Following the completion of the sale, the executive vice president directly owned 9,444 shares in the company, valued at approximately $995,019.84. The trade was a 3.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 16,788 shares of company stock worth $1,785,633. Insiders own 4.50% of the company's stock.

Institutional Trading of Addus HomeCare

A number of large investors have recently added to or reduced their stakes in ADUS. Freestone Grove Partners LP increased its stake in Addus HomeCare by 5,035.2% in the 4th quarter. Freestone Grove Partners LP now owns 137,932 shares of the company's stock worth $14,813,000 after acquiring an additional 135,246 shares during the last quarter. Empowered Funds LLC boosted its holdings in shares of Addus HomeCare by 186.1% in the 4th quarter. Empowered Funds LLC now owns 70,927 shares of the company's stock worth $7,617,000 after purchasing an additional 46,137 shares during the period. Adage Capital Partners GP L.L.C. purchased a new position in shares of Addus HomeCare in the 2nd quarter worth approximately $4,838,000. Punch & Associates Investment Management Inc. boosted its holdings in shares of Addus HomeCare by 29.1% in the 3rd quarter. Punch & Associates Investment Management Inc. now owns 143,655 shares of the company's stock worth $16,950,000 after purchasing an additional 32,355 shares during the period. Finally, Raymond James Financial Inc. boosted its holdings in shares of Addus HomeCare by 5,969.5% in the 3rd quarter. Raymond James Financial Inc. now owns 32,047 shares of the company's stock worth $3,781,000 after purchasing an additional 31,519 shares during the period. Institutional investors own 95.35% of the company's stock.

About Addus HomeCare

Addus HomeCare NASDAQ: ADUS is a leading provider of home and community-based care services for elderly, disabled, and medically complex individuals across the United States. Through a network of company-owned and franchise locations, the company delivers a broad spectrum of non-medical personal care and licensed home health services designed to support clients' independence and quality of life.

The company's core offerings include personal care assistance—covering daily living activities, medication reminders, and light housekeeping—and skilled home health services delivered under the supervision of registered nurses and licensed therapists.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.